secwatch.observer — SEC 8-K summary
======================================

Issuer:     Absci Corp (ABSI)
CIK:        0001672688
Form:       8-K
Filed at:   2024-09-04T23:59:59+00:00
Accession:  0001628280-24-039225
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Absci completes first milestone in AstraZeneca oncology collaboration; AI-designed antibodies delivered
--------------------------------------------------------------------------------

- Absci delivered AI-designed antibody sequences to AstraZeneca, fulfilling first milestone under December 2023 collaboration.
- AstraZeneca elected to advance sequences into AI-lead optimization phase.
- Collaboration combines Absci's Integrated Drug Creation platform with AstraZeneca's oncology expertise.
- Goal: accelerate discovery of a potential new cancer treatment candidate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672688/000162828024039225/0001628280-24-039225-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672688/000162828024039225/absc-20240904.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-039225

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer